Q Suvoda Launches eCOA-Specific Language and Design Toolkit and Enters…

Suvoda LLC

PHILADELPHIA, Oct. 19 /PRNewswire/

Practical, innovative functionality is designed to reduce eCOA burdens, reduce time to market and improve site, clinician and patient experiences

Suvoda LLC, a global clinical trial technology company specializing in complex trials in therapeutic areas such as oncology, central nervous system (CNS) and rare diseases, today announced that its electronic clinical outcome assessment (eCOA) solution is part of the launch of a single platform in the second phase of the early adopter program. Designed to work seamlessly with Suvoda IRT and eConsent, this solution focuses on eliminating inefficiencies that eCOA continues to struggle with, such as: B. Gaps in overall delivery and execution quality, time-consuming translation and localization processes, and the logistics of device management.

“eCOA is not a new concept, but the full promise of this eClinical technology has yet to be realized by sponsors and CROs, and most importantly, clinical trial participants,” said Jill Platko, Vice President, Scientific Services at Suvoda Suvoda’s mission to improve the clinical trial process meant that Suvoda didn’t just want to offer another eCOA solution, we wanted to fill the gaps that make current eCOA implementations so difficult.”

Practical innovations simplify eCOA implementation

In the next phase of the early adopter program, Suvoda’s eCOA solution takes customer input into account and includes redesigned processes in four key areas that have proven critical to successful eCOA implementations:

1. Design and creation of questionnaires

Suvoda eCOA introduces a unique, easy-to-use, configuration-based toolkit that simplifies and speeds up the setup and implementation of eCOAs. In it, Suvoda offers its proprietary domain-specific language and authoring tool tailored for eCOA questionnaires.

As an innovative addition to the current eCOA product landscape, this tool simplifies the creation of eCOA questionnaires, accelerates localization and improves access to previews. Questionnaires can also be defined, customized, translated, validated and reused across different modalities and devices, all in a compliant environment. This licensing and localization capability includes direct access for translation providers to further streamline workflows and schedules to better meet the needs of any protocol now and in the future.

2.unit logistics

With 10 years of experience handling the most urgent situations across thousands of investigations around the world with its IRT solution and support, Suvoda is uniquely positioned to set the standard for eCOA unit logistics. eCOA puts the user experience first. With proven clinical trial supply chain and data management processes, Suvoda eCOA will further improve real-time data collection and simplify device logistics for global clinical trial sites, sponsors and patients.

3.Customer care/support in real time

With the global capability of its equipment and locations, Suvoda supports business-critical issues in real-time, furthering its reputation for responsive and reliable customer service. Consistent with a consistently high customer satisfaction score, the company has prioritized the same level of global support for all of its eCOA customers.

4.Integrity of patient data through a single platform approach

Suvoda’s eCOA paired with its market-leading IRT solution on a single, organically built platform together with eConsent ensures a worry-free, streamlined approach, reducing the number of integrations required for a clinical trial. This transparent integration ensures that patient data is seamlessly captured and shared across the platform, giving users better access to normalized, compatible, unified and analytics-ready data. This is a significant advance that improves data integrity, positively impacts study schedule and outcomes, and creates a more consistent user experience for patients and on-site practitioners.

“With a proven track record of delivering and executing services for thousands of clinical trials around the world, Suvoda specializes in meeting the demands of mission-critical, time-sensitive patient interactions,” said EK Koh, Suvoda’s Chief Product Officer We’re logistics leader in clinical trials – and the addition of eCOA to our platform ensures that we put the patient’s digital experience at the center without adding complexity.”

Suvoda is still accepting participants in its early adopter program while eCOA moves on to the next phase. Additional expansions will be released in early 2023. Click here to inquire about participation in the early adopter program.

Information about Suvoda

Suvoda is a global clinical trials technology company specializing in complex, life-sustaining trials in therapeutic areas such as oncology, central nervous system (CNS) and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda enables clinical trial professionals to handle even the most urgent situations in the most urgent trials through advanced software solutions on a single platform. Headquartered outside of Philadelphia, Suvoda also has offices in Portland, Oregon, Barcelona, ​​Spain, Bucharest, Romania and Tokyo, Japan. The company boasts a consistent Net Promoter Score (NPS) of around 70, well above the tech industry average of 50, and has been chosen by study sponsors and CROs to already support more than 1,000 studies in 65 countries. Visit suvoda.com for more information. Follow Suvoda further Twitter and LinkedIn.

Media contact:

Morgan Reese, morgan.reese@clydegroup.com
Logo – https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg
See original content: https://www.prnewswire.com/news-releases/q-suvoda-launches-ecoa-specific-language-and-design-toolkit-and-goes-to-the-second-phase-of- the-early-adopter-program-about-301696335.html

Original content from: Suvoda LLC, transmitted by news aktuell

Leave a Comment